Bazedoxifene acetate formulations

1. A pharmaceutical composition comprising:

a pharmaceutically effective amount of bazedoxifene acetate, wherein at least 80% of said bazedoxifene acetate is present in the A polymorph form, and

a carrier or excipient system, the carrier or excipient system comprising:

a) a first filler/diluent component comprising from about 5% to about 85% by weight of the pharmaceutical formulation;

b) an optional second filler/diluent component comprising from about 5% to about 85% by weight of the pharmaceutical formulation;

c) an optional antioxidant component comprising up to about 15% by weight of the pharmaceutical formulation;

d) a glidant/disintegrant component comprising from about 0.01% to about 10% by weight of the pharmaceutical formulation; and

e) a lubricant component comprising from about 0.01% to about 10% by weight of the pharmaceutical formulation.

2. A pharmaceutical composition of claim 1 , wherein said bazedoxifene acetate comprises from about 0.1% to about 30% by weight of the pharmaceutical formulation.

3. A pharmaceutical composition of claim 1 , wherein said bazedoxifene acetate comprises from about 10% to about 30% by weight of the pharmaceutical formulation.

4. A pharmaceutical composition of claim 1 , wherein said bazedoxifene acetate is present in the A polymorph form.

5. A pharmaceutical composition of claim 1 , wherein at least 90% of said bazedoxifene acetate is present in the A polymorph form.

6. A pharmaceutical composition of claim 1 , wherein:

said bazedoxifene acetate comprises from about 10% to about 30% by weight of the pharmaceutical formulation;

said first filler/diluent component comprising from about 25% to about 50% by weight of the pharmaceutical formulation;

said optional second filler/diluent component comprising from about 25% to about 50% by weight of the pharmaceutical formulation; said optional antioxidant component comprising from about 1% to about 10% by weight of the pharmaceutical formulation;

said glidant/disintegrant component comprising from about 1% to about 10% by weight of the pharmaceutical formulation; and

said lubricant component comprising about 0.01% to about 3% by weight of the pharmaceutical formulation.

7. A pharmaceutical composition of claim 6 , wherein:

said first filler/diluent component comprising from about 25% to about 42% by weight of the pharmaceutical formulation; and

said optional second filler/diluent component comprising from about 25% to about 42% by weight of the pharmaceutical formulation.

8. A pharmaceutical composition of claim 1 , wherein said first filler/diluent component comprises one or more components selected from the group consisting of sugars, mannitol, lactose, sucrose, powdered cellulose, microcrystalline cellulose, malodextrin, sorbitol, starch, xylitol, carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl celluloses, microcrystalline celluloses, starches, anhydrous dicalcium phosphate, sodium starch glycolates, and metal aluminosilicates.

9. A pharmaceutical composition of claim 1 , wherein the filler/diluent component comprises microcrystalline cellulose.

10. A pharmaceutical composition of claim 1 , wherein said optional second filler/diluent component comprises one or more components selected from the group consisting of sugars, mannitol, lactose, sucrose, powdered cellulose, microcrystalline cellulose, malodextrin, sorbitol, starch, xylitol, carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl celluloses, microcrystalline celluloses, starches, anhydrous dicalcium phosphate, sodium starch glycolates, and metal aluminosilicates.

11. A pharmaceutical composition of claim 1 , wherein said optional second filler/diluent component comprises lactose.

12. A pharmaceutical composition of claim 1 , wherein the glidant/disintegrant component comprises one or more components selected from the group consisting of croscarmellose sodium, modified cellulose, pregelatinized starch, sodium starch glycolate, crospovidone, starch, alginic acid, sodium alginate, clays, cellulose floc, ion exchange resins, effervescent systems based on food acids, amorphous fumed silica, talc, lactose, metal stearates, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, silica, silicon dioxide and silicon dioxide aerogels.

13. A pharmaceutical composition of claim 1 , wherein said glidant/disintegrant component comprises sodium starch glycolate.

14. A pharmaceutical composition of claim 1 , wherein said lubricant component comprises one or more components selected from the group consisting of metal stearates, fatty acid esters, fatty acids, fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols, amorphous fumed silica, and sodium chloride.

15. A pharmaceutical composition of claim 1 , wherein said lubricant component comprises magnesium stearate.

16. A pharmaceutical composition of claim 1 , wherein said optional antioxidant component comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, BHT or BHA.

17. A pharmaceutical composition of claim 1 , wherein said optional antioxidant component comprises ascorbic acid.

18. A pharmaceutical composition of claim 1 , wherein:

said first filler/diluent component comprises one or more components selected from the group consisting of sugars, mannitol, lactose, sucrose, powdered cellulose, microcrystalline cellulose, malodextrin, sorbitol, starch, xylitol, carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl celluloses, microcrystalline celluloses, starches, anhydrous dicalcium phosphate, sodium starch glycolates, or metal aluminosilicates;

said optional second filler/diluent component comprises one or more components selected from the group consisting of sugars, mannitol, lactose, sucrose, powdered cellulose, microcrystalline cellulose, malodextrin, sorbitol, starch, xylitol, carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl celluloses, microcrystalline celluloses, starches, anhydrous dicalcium phosphate, sodium starch glycolates, or metal aluminosilicates;

said optional antioxidant component comprises one or more components selected from the group consisting of ascorbic acid, sodium ascorbate or ascorbyl palmitate;

said glidant/disintegrant component comprises one or more components selected from the group consisting of croscarmellose sodium, modified cellulose, pregelatinized starch, sodium starch glycolate, crospovidone, starch, alginic acid, sodium alginate, clays, cellulose floc, ion exchange resins, effervescent systems based on food acids, amorphous fumed silica, talc, lactose, metal stearates, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, silica, silicon dioxide and silicon dioxide aerogels; and

said lubricant component comprises one or more components selected from the group consisting of metal stearates, fatty acid esters, fatty acids, fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols, amorphous fumed silica, and sodium chloride.

19. A pharmaceutical composition of claim 1 , wherein:

said first filler/diluent component comprises microcrystalline cellulose;

said optional second filler/diluent component comprises a sugar;

said optional antioxidant component comprises ascorbic acid;

said glidant/disintegrant component comprises sodium starch glycolate; and

said lubricant component comprises a metal stearate.

20. A pharmaceutical composition of claim 1 , wherein:

said first filler/diluent component comprises microcrystalline cellulose;

said optional second filler/diluent component comprises lactose NF;

said optional antioxidant component comprises ascorbic acid;

said glidant/disintegrant component comprises sodium starch glycolate; and

said lubricant component comprises magnesium stearate.

21. A pharmaceutical composition of claim 7 , wherein:

said first filler/diluent component comprises microcrystalline cellulose;

said optional second filler/diluent component comprises lactose NF;

said optional antioxidant component comprises ascorbic acid;

said glidant/disintegrant component comprises sodium starch glycolate; and

said lubricant component comprises magnesium stearate.

22. A pharmaceutical composition of claim 1 , wherein the composition contains from about 0.1 mg to about 300 mg of said bazedoxifene acetate.

23. A pharmaceutical composition of claim 1 , wherein the composition contains from about 0.5 mg to about 230 mg of said bazedoxifene acetate.

24. A pharmaceutical composition of claim 1 , wherein the composition contains from about 1 mg to about 170 mg of said bazedoxifene acetate.

25. A pharmaceutical composition of claim 1 , wherein the composition contains from about 5 mg to about 115 mg of said bazedoxifene acetate.

26. A pharmaceutical composition of claim 1 , wherein the composition contains from about 1 mg to about 30 mg of said bazedoxifene acetate.

27. A tablet comprising a pharmaceutical composition of claim 1 .

28. A tablet comprising a pharmaceutical composition of claim 3 .

29. A tablet comprising a pharmaceutical composition of claim 18 .

30. A tablet comprising a pharmaceutical composition of claim 21 .

31. A tablet of claim 27 further comprising one or more coatings.

32. A pharmaceutical composition of claim 1 wherein said composition is prepared by a non-aqueous process.

33. A pharmaceutical composition of claim 32 wherein said non-aqueous process is direct blending.

34. A pharmaceutical composition of claim 32 wherein said non-aqueous process is dry granulation.

35. A pharmaceutical composition of claim 32 wherein said non-aqueous process is roller compaction.

36. A tablet comprising a composition according to any of claims 32 - 35 .

37. A capsule containing a composition according to any of claims 32 - 35 .

38. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is prepared by a non-aqueous process comprising direct blending, dry granulation, or roller compaction.

39. The pharmaceutical composition of claim 38 , wherein the non-aqueous process is a direct blend process comprising:

i) combining the bazedoxifene acetate, first filler/diluent, second filler/diluent, glidant, and, optionally, the antioxidant to form a first mixture;

ii) blending the first mixture to form a blended first mixture;

iii) adding the lubricant to the blended first mixture to form a second mixture; and

iv) optionally blending the second mixture to form a blended second mixture; and

v) optionally,

compressing at least a portion of the second mixture, or the blended second mixture, to form a tablet therefrom; or

filling a capsule with the second mixture, or the blended second mixture, to provide a capsule filled with the second mixture, or the blended second mixture.

40. The pharmaceutical composition of claim 38 , wherein at least 90% of the bazedoxifene acetate is present in the A polymorph form.

41. The pharmaceutical composition of claim 39 , wherein at least 90% of the bazedoxifene acetate is present in the A polymorph form.

42. The pharmaceutical composition of claim 39 , wherein:

the first filler/diluent component comprises one or more components selected from the group consisting of sugars, mannitol, lactose, sucrose, powdered cellulose, microcrystalline cellulose, malodextrin, sorbitol, starch, xylitol, carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl celluloses, microcrystalline celluloses, starches, anhydrous dicalcium phosphate, sodium starch glycolates, or metal aluminosilicates;

the optional second filler/diluent component comprises one or more components selected from the group consisting of sugars, mannitol, lactose, sucrose, powdered cellulose, microcrystalline cellulose, malodextrin, sorbitol, starch, xylitol, carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl celluloses, microcrystalline celluloses, starches, anhydrous dicalcium phosphate, sodium starch glycolates, or metal aluminosilicates;

the optional antioxidant component comprises one or more components selected from the group consisting of ascorbic acid, sodium ascorbate or ascorbyl palmitate;

the glidant/disintegrant component comprises one or more components selected from the group consisting of croscarmellose sodium, modified cellulose, pregelatinized starch, sodium starch glycolate, crospovidone, starch, alginic acid, sodium alginate, clays, cellulose floc, ion exchange resins, effervescent systems based on food acids, amorphous fumed silica, talc, lactose, metal stearates, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, silica, silicon dioxide and silicon dioxide aerogels; and

the lubricant component comprises one or more components selected from the group consisting of metal stearates, fatty acid esters, fatty acids, fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols, amorphous fumed silica, and sodium chloride.

43. The pharmaceutical composition of claim 38 , wherein:

the first filler/diluent component comprises microcrystalline cellulose;

the optional second filler/diluent component comprises lactose;

the optional antioxidant component comprises ascorbic acid;

the glidant/disintegrant component comprises sodium starch glycolate; and

the lubricant component comprises a metallic stearate.

44. The pharmaceutical composition of claim 38 , wherein:

the first filler/diluent component comprises microcrystalline cellulose;

the optional second filler/diluent component comprises lactose NF;

the optional antioxidant component comprises ascorbic acid;

the glidant/disintegrant component comprises sodium starch glycolate; and

the lubricant component comprises magnesium stearate.

45. The pharmaceutical composition of claim 39 , wherein:

the first filler/diluent component comprises microcrystalline cellulose;

the optional second filler/diluent component comprises lactose NF;

the optional antioxidant component comprises ascorbic acid;

the glidant/disintegrant component comprises sodium starch glycolate; and

the lubricant component comprises magnesium stearate.

46. The pharmaceutical composition of claim 38 , wherein the pharmaceutical composition contains from about 0.1 mg to about 300 mg of the bazedoxifene acetate.

47. The pharmaceutical composition of claim 39 , wherein the pharmaceutical composition contains from about 0.1 mg to about 300 mg of the bazedoxifene acetate.